Stockscreener 앱 받기
1.24
2.36%
-0.03
시간 외 거래:
1.24
전일 마감가:
$1.27
열려 있는:
$1.28
하루 거래량:
122.86K
Relative Volume:
0.26
시가총액:
$38.88M
수익:
-
순이익/손실:
$-69.00M
주가수익비율:
-0.446
EPS:
-2.78
순현금흐름:
$-55.26M
1주 성능:
-1.59%
1개월 성능:
-5.34%
6개월 성능:
-79.40%
1년 성능:
-82.73%
1일 변동 폭
$1.22
$1.285
1주일 범위
$1.22
$1.35
52주 변동 폭
$1.05
$10.16
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
명칭
Acrivon Therapeutics Inc
전화
617-207-8979
주소
480 ARSENAL WAY, SUITE 100, WATERTOWN
ACRV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.24 | 40.45M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-05 | 재개 | Piper Sandler | Overweight |
| 2025-01-31 | 개시 | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | 개시 | JMP Securities | Mkt Outperform |
| 2023-12-15 | 재개 | Jefferies | Buy |
| 2023-10-05 | 개시 | Maxim Group | Buy |
| 2023-06-02 | 개시 | Oppenheimer | Outperform |
| 2023-05-08 | 개시 | BMO Capital Markets | Outperform |
| 2023-04-27 | 개시 | Ladenburg Thalmann | Buy |
| 2023-04-20 | 개시 | H.C. Wainwright | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-12-12 | 개시 | Jefferies | Buy |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
모두보기
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
How to integrate Acrivon Therapeutics Inc. into portfolio analysis toolsFree AI Driven Stock Trend Forecast - Newser
Acrivon Therapeutics (ACRV) Expected to Announce Earnings on Tuesday - Defense World
Momentum divergence signals in Acrivon Therapeutics Inc. chartFree Real Profit Trade Plan Suggestions - Newser
Real time alert setup for Acrivon Therapeutics Inc. performanceAI Trading Forecast Based on Big Data - Newser
Best data tools to analyze Acrivon Therapeutics Inc. stockEquity Portfolio Outlook and Performance Summary - Newser
Published on: 2025-08-09 07:13:49 - Newser
How to recover losses in Acrivon Therapeutics Inc. stockFree Reversal Alert Based on RSI Indicator - Newser
How Acrivon Therapeutics Inc. stock performs during market volatilityFree Consistent Profit Pattern Recognition Tools - Newser
What makes Acrivon Therapeutics Inc. stock price move sharplyTriple Digit Gain Opportunity Watchlist - Newser
Statistical indicators supporting Acrivon Therapeutics Inc.’s strengthEntry Confirmation Using Short-Term Forecasting - Newser
Is Acrivon Therapeutics Inc. stock a good hedge against inflationSmart Trend Analysis With Buy Point Cues - Newser
Real time breakdown of Acrivon Therapeutics Inc. stock performanceAI Triggered Buy Zone Forecast System - Newser
Short interest data insights for Acrivon Therapeutics Inc.Free Triple Digit Growth Focused Trade Plan - Newser
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
How high can Acrivon Therapeutics Inc. stock price go in 2025Free Secure Return Focused Investment Plan - Newser
What moving averages say about Acrivon Therapeutics Inc.Early Entry Ideas with Momentum Potential - Newser
Tools to monitor Acrivon Therapeutics Inc. recovery probabilityFree Profit Target Stock Opportunity Monitor - Newser
Why Acrivon Therapeutics Inc. stock attracts strong analyst attentionFree AI Driven Buy Alert Trade Blueprint - Newser
Using economic indicators to assess Acrivon Therapeutics Inc. potentialHigh Yield Watchlist with Filtered Picks - Newser
Detecting support and resistance levels for Acrivon Therapeutics Inc.Trade Setup Builder with Custom Alerts - Newser
Will breakout in Acrivon Therapeutics Inc. lead to full recoveryRisk Balanced Picks for Safer Trading - Newser
Candlestick Reversal Detected on Acrivon Therapeutics Inc.’s ChartShort Term Buy Zone Stock Alerts Signal Entry - metal.it
Cantor Fitzgerald sets Acrivon stock to Overweight on AP3 platform - MSN
What institutional investors are buying Acrivon Therapeutics Inc. stockStrongest growth potential - Jammu Links News
When is Acrivon Therapeutics Inc. stock expected to show significant growthFree Consultation - Jammu Links News
How does Acrivon Therapeutics Inc. generate profit in a changing economyFree Investment Timing Strategies - Jammu Links News
What analysts say about Acrivon Therapeutics Inc. stockTrack top-performing stocks in real-time - Jammu Links News
What catalysts could drive Acrivon Therapeutics Inc. stock higher in 2025Outstanding capital appreciation - Jammu Links News
Is Acrivon Therapeutics Inc. stock overvalued or undervaluedMaximize gains with data-driven stock picks - Jammu Links News
Is Acrivon Therapeutics Inc. a growth stock or a value stockMaximize portfolio value with smart investment plans - Jammu Links News
Should I hold or sell Acrivon Therapeutics Inc. stock in 2025Explosive earning power - Jammu Links News
How does Acrivon Therapeutics Inc. compare to its industry peersAccess high-quality stock research instantly - Jammu Links News
What are analysts’ price targets for Acrivon Therapeutics Inc. in the next 12 monthsMaximize returns with disciplined trading approaches - Jammu Links News
What are the technical indicators suggesting about Acrivon Therapeutics Inc.Get daily updates on the hottest stocks - Jammu Links News
What is Acrivon Therapeutics Inc. company’s growth strategySmart Portfolio Data Feed For 2025 - Jammu Links News
Acrivon Therapeutics Inc (ACRV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):